Does Benzene Cause Acute Myeloid Leukemia?

From General Health to Occupational Exposure

The legacy context of general health and science information often addresses broad public concerns, such as the impact of lifestyle changes during the COVID-19 pandemic on alcohol consumption. This heritage includes discussions on maintaining healthy relationships with substances and recognizing when use becomes problematic, emphasizing physical and psychological well-being. Such themes naturally extend to examining environmental factors that may influence health risks over time. In occupational settings, workers in industries like chemical manufacturing or petroleum refining may face distinct exposures that warrant focused attention. Among these, benzene—a common industrial solvent and component of crude oil—has been studied for its potential long-term health effects. The transition from general health awareness to occupational exposure concern involves shifting from population-level lifestyle advice to specific workplace hazards. This pivot highlights how chronic, low-level contact with certain agents in professional environments can elevate risks for serious conditions, including hematological malignancies. The focus here is on the exposure pathway itself, rather than detailed disease mechanisms, aligning with the need to understand causation in occupational health contexts.

Benzene as a Myelotoxin and Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene has been consistently linked to an increased risk of developing acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as anemia, thrombocytopenia, and neutropenia, leading to fatigue, bleeding, and recurrent infections. Diagnosis is confirmed through bone marrow aspiration and biopsy, demonstrating at least 20% blasts in the marrow or blood, along with cytogenetic and molecular testing to classify subtypes and guide treatment. Benzene is metabolized in the liver and bone marrow to reactive intermediates, including benzene oxide, phenol, hydroquinone, and benzoquinone. These metabolites can form DNA adducts, induce oxidative stress, and cause chromosomal aberrations. The carcinogenic ability of benzene has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Mechanisms and Epidemiological Evidence

The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of acute myeloid leukaemia (AML) (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by the myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). Epidemiological studies have further quantified the risk. In a meta-analysis of childhood cancers, findings indicated an elevated risk of acute lymphoblastic leukemia in children exposed to PM2.5, and increased risks of all childhood cancers and acute myeloid leukemia associated with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). Specifically, the odds ratio for AML was 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). Previous studies established a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Risk Communication and Implications

Regarding risk communication and warnings, the adequacy of warnings regarding benzene and AML is a critical consideration for affected patients. Given the established causal link, warnings should clearly communicate the risks of occupational and environmental exposure, particularly for workers in industries such as chemical manufacturing, petroleum refining, and rubber production. The timeline between exposure and documented harm can vary, but the latency period for benzene-induced AML is typically several years to decades, depending on exposure intensity and duration. For patients diagnosed with AML who have a history of benzene exposure, causation-related considerations include assessing the cumulative exposure level, latency, and absence of other known risk factors. These factors are important for medical-legal evaluations and for informing patients about potential occupational or environmental origins of their disease. In summary, the evidence strongly supports that benzene causes acute myeloid leukemia through multiple mechanistic pathways, including genotoxicity, oxidative stress, and immunosuppression. Epidemiological data consistently show elevated risks at occupational exposure levels of 10 ppm or more and even at lower environmental levels in children. Adequate warnings and risk communication are essential to prevent exposure and to assist in the medical and legal evaluation of affected individuals.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence that benzene causes acute myeloid leukemia?

Benzene is a well-established human carcinogen. Multiple studies have shown a causal relationship between occupational benzene exposure and AML. Mechanisms include genotoxicity, oxidative stress, and immunosuppression. Epidemiological data show elevated risks at exposure levels of 10 ppm or more, with odds ratios of 1.22 per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

What are the typical latency periods for benzene-induced AML?

The latency period for benzene-induced AML typically ranges from several years to decades, depending on the intensity and duration of exposure. This variability underscores the importance of long-term monitoring for individuals with significant occupational or environmental benzene exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.